More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$677206244
EPS
-5.44
P/E ratio
--
Price to sales
0.34
Dividend yield
--
Beta
0.77173
Previous close
$10.21
Today's open
$10.15
Day's range
$9.82 - $10.64
52 week range
$9.82 - $35.58
show more
CEO
Brian J. Blaser
Employees
6500
Headquarters
San Diego, CA
Exchange
Nasdaq Global Select
Shares outstanding
68612588
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
QuidelOrtho (QDEL) Securities Investigation Notice - Levi & Korsinsky
QuidelOrtho shares fell roughly 14% after third-quarter 2026 results showed China revenue down 45% and respiratory revenue down 39%. Levi & Korsinsky is investigating on behalf of investors who lost money.
PRNewsWire • Nov 16, 2026

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving QuidelOrtho (QDEL)
Point-of-Care revenue down 27% and total sales down roughly 12% year over year: QuidelOrtho's third-quarter 2026 revenue miss against Wall Street consensus sent shares down approximately 14% Point-of-Care revenue down 27% and total sales down roughly 12% year over year: QuidelOrtho's third-quarter 2026 revenue miss against Wall Street consensus sent shares down approximately 14%
GlobeNewsWire • Nov 12, 2026

Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
PRNewsWire • Nov 12, 2026

QuidelOrtho Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of QuidelOrtho Corporation - QDEL
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) (NasdaqGS: QDEL). According to a securities class action filed against the Company, internal reports and accounts from former employees described serious and unresolved problems with the Company's flagship test, the Savanna Re.
Business Wire • Nov 11, 2026

QDEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving QuidelOrtho
QuidelOrtho's May 2026 quarterly report said China's volume-based procurement program would not likely have a material impact on total annualized revenue. Third-quarter 2026 results showed China revenue down 45%, and QDEL shares fell roughly 14%.
PRNewsWire • Nov 10, 2026

QuidelOrtho Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into QuidelOrtho (QDEL)
QuidelOrtho narrowed its full-year revenue outlook and announced a restructuring program with its third-quarter 2026 results, and shares fell roughly 14%. QDEL shareholders who lost money have rights, and Levi & Korsinsky is investigating potential securities law violations.
PRNewsWire • Nov 9, 2026

QuidelOrtho Corporation (QDEL) Q3 2026 Earnings Call Transcript
QuidelOrtho Corporation ( QDEL ) Q3 2026 Earnings Call November 3, 2026 5:00 PM EST Company Participants Sanjeev Sharma Brian Blaser - President, CEO & Director Micah Young - Chief Financial Officer & Principal Financial Officer Conference Call Participants William Bonello - Craig-Hallum Capital Group LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Operon Research, LLC Casey Woodring - JPMorgan Chase & Co, Research Division Presentation Operator Welcome to the QuidelOrtho Third Quarter 2026 Financial Results Conference Call and webcast. [Operator Instructions] Please note, this conference call is being recorded.
Seeking Alpha • Nov 4, 2026

What QuidelOrtho (QDEL) Said on Its Q3 Earnings Call
QuidelOrtho NASDAQ: QDEL reported third-quarter revenue of $619 million, down 12% year over year on a constant-currency basis, as China pricing changes and softer respiratory testing demand continued to weigh on results. The company said revenue rose 3% excluding China, respiratory testing and the prior-year contribution from its U.S. Donor Screening business, which it is winding down.
MarketBeat • Nov 4, 2026

QuidelOrtho Reports Third Quarter 2026 Financial Results
― Growth in Labs and Immunohematology Outside of China Highlights Underlying Business Strength ― ― New Cost Transformation and Enterprise Restructuring Program Expected to Deliver Over $80 Million in Annual Savings in 2027 ― ― Updated Full-Year 2026 Financial Guidance Narrowing Prior Ranges ― SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, today announced financial results for the third quarter ended September 27, 2026. Key Third Quarter 2026 Results: (all comparisons are to the prior year period) Total revenue was $619 million, a decrease of 12% both as reported and in constant currency.
PRNewsWire • Nov 3, 2026

QuidelOrtho (QDEL) Beats Q3 Earnings and Revenue Estimates
QuidelOrtho (QDEL) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.8 per share a year ago.
Zacks Investment Research • Nov 3, 2026

¹ Disclosures

Open an M1 investment account to buy and sell QuidelOrtho Corp Com commission-free¹. Build wealth for the long term using automated trading and transfers.